PMC:7162774 / 4103-4382 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"140","span":{"begin":115,"end":122},"obj":"Species"},{"id":"143","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"144","span":{"begin":57,"end":76},"obj":"Chemical"},{"id":"145","span":{"begin":139,"end":158},"obj":"Chemical"},{"id":"149","span":{"begin":241,"end":259},"obj":"Disease"}],"attributes":[{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"Tax:9606"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"MESH:D053139"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"MESH:C558899"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"MESH:C558899"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"MESH:D006932"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T52","span":{"begin":0,"end":11},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T53","span":{"begin":57,"end":66},"obj":"CHEBI:31781;CHEBI:31781;DG_23"},{"id":"T54","span":{"begin":67,"end":76},"obj":"CHEBI:45409;CHEBI:45409;DG_30"},{"id":"T55","span":{"begin":139,"end":148},"obj":"CHEBI:31781;CHEBI:31781;DG_23"},{"id":"T56","span":{"begin":149,"end":158},"obj":"DG_30"},{"id":"T87166","span":{"begin":0,"end":11},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T36846","span":{"begin":57,"end":66},"obj":"CHEBI:31781;CHEBI:31781;DG_23"},{"id":"T33068","span":{"begin":67,"end":76},"obj":"CHEBI:45409;CHEBI:45409;DG_30"},{"id":"T73640","span":{"begin":139,"end":148},"obj":"CHEBI:31781;CHEBI:31781;DG_23"},{"id":"T95625","span":{"begin":149,"end":158},"obj":"DG_30"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T35","span":{"begin":241,"end":259},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0002408"},{"id":"A36","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0024288"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"T18","span":{"begin":57,"end":76},"obj":"Chemical"},{"id":"T19","span":{"begin":57,"end":66},"obj":"Chemical"},{"id":"T20","span":{"begin":67,"end":76},"obj":"Chemical"},{"id":"T21","span":{"begin":139,"end":148},"obj":"Chemical"},{"id":"T22","span":{"begin":149,"end":158},"obj":"Chemical"}],"attributes":[{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}

{"project":"LitCovid-sentences","denotations":[{"id":"T28","span":{"begin":0,"end":279},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T33","span":{"begin":241,"end":259},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0002904"}],"text":"Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9."}